Bio-Rad Laboratories, Inc.

BIO.B Healthcare Medical Devices

Bio-Rad Laboratories, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.6 billion, up 0.65% from fiscal 2024.

Revenue
+0.52%
EPS
+234.8%
Free cash flow
+8.07%
Total debt
+0.11%

Quarter to September 2026, against a year earlier

379.50 15.35 +4.22%
Market cap
$10.3B
P/E
9.9×
Fwd P/E
—
Dividend yield
—
F-score
5/9
Altman Z
3.24
Beneish M
−2.29
Dividend safety
n/a
Older periods Dec '25 Mar '26 Jun '26 Sep '26
P/E ratio

+8 more quarters

11.12 45.54 35.59 9.57
P/S ratio
3.28 2.90 3.06 3.77
P/FCF ratio
22.49 20.87 22.33 29.53
P/Operating CF
51.37 69.39 80.34 101.42
P/B ratio
1.14 1.09 1.11 1.29
EV/Sales
3.15 2.76 2.90 3.59
EV/EBITDA
172.31 123.95 141.53 0.00
EV/FCF
21.59 19.87 21.16 28.14
Current Ratio
5.62 3.21 3.14 3.18
Net Debt/EBITDA
2.84 (10.60) (5.71) 9.26
Debt/Equity
0.16 0.18 0.17 0.16
Earnings Yield
9.00% 2.20% 2.81% 10.45%
Free Cash Flow Yield
4.45% 4.79% 4.48% 3.39%
Free Cash Flow per Share
4.37 2.90 2.49 2.43
Book value per Share
273.40 254.15 268.22 283.91
Free Cash Flow
119.10 78.20 66.60 65.20
EV/EBIT
172.31 123.95 141.53 0.00
Other line items

Show all line items

Columns are period end dates · fundamentals updated 6 Nov 2026